Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 14
Submit an article Journal homepage
186
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Limited efficacy of high-dose methotrexate to prevent the central nervous system relapse in patients with IVLBCL

Toshiki TeraoDivision of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6728-3346
ORCID Icon,
Takafumi TsushimaDivision of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan
,
Daisuke IkedaDivision of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan
,
Ami FukumotoDivision of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan
,
Yuya KamuraDivision of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan
,
Ayumi KuzumeDivision of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan
,
Rikako TabataDivision of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan
,
Daisuke MiuraDivision of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan
,
Kentaro NaritaDivision of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, JapanORCID Iconhttps://orcid.org/0000-0002-6504-9046
ORCID Icon,
Masami TakeuchiDivision of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan
&
Kosei MatsueDivision of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, JapanORCID Iconhttps://orcid.org/0000-0002-8669-9865
ORCID Icon show all
Pages 3394-3401 | Received 01 Jul 2022, Accepted 02 Sep 2022, Published online: 16 Sep 2022

References

  • Shimada K, Murase T, Matsue K, et al. Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients. Cancer Sci. 2010;101(6):1480–1486.
  • Shimada K, Yamaguchi M, Atsuta Y, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(4):593–602.
  • Matsue K, Abe Y, Narita K, et al. Diagnosis of intravascular large B cell lymphoma: novel insights into clinicopathological features from 42 patients at a single institution over 20 years. Br J Haematol. 2019;187(3):328–336.
  • Wang W, Zhang Y, Zhang L, et al. Intravenous methotrexate at a dose of 1 g/m(2) incorporated into RCHOP prevented CNS relapse in high-risk DLBCL patients: a prospective, historic controlled study. Am J Hematol. 2020;95(4):E80–e83.
  • Puckrin R, El Darsa H, Ghosh S, et al. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma. Am J Hematol. 2021;96(7):764–771.
  • Orellana-Noia VM, Reed DR, McCook AA, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022;139(3):413–423.
  • Jeong H, Cho H, Kim H, et al. Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis. Blood Adv. 2021;5(8):2142–2152.
  • Kobayashi H, Abe Y, Miura D, et al. Limited efficacy of high-dose methotrexate in patients with neurolymphomatosis. Int J Hematol. 2019;109(3):286–291.
  • Ferreri AJ, Reni M, Foppoli M, International Extranodal Lymphoma Study Group (IELSG), et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512–1520.
  • Abe Y, Narita K, Kobayashi H, et al. Clinical value of abnormal findings on brain magnetic resonance imaging in patients with intravascular large B-cell lymphoma. Ann Hematol. 2018;97(12):2345–2352.
  • Grisariu S, Avni B, Batchelor TT, et al. Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood. 2010;115(24):5005–5011.
  • Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
  • Pitman SW, Frei E 3rd. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin’s lymphoma. Cancer Treat Rep. 1977;61(4):695–701.
  • Joerger M, Huitema AD, Illerhaus G, et al. Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma. Leuk Lymphoma. 2012;53(10):1867–1875.
  • Wilson MR, Eyre TA, Martinez-Calle N, et al. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery. Blood Adv. 2020;4(15):3586–3593.
  • Narita Y, Nagane M, Mishima K, et al. Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol. 2021;23(1):122–133.
  • Younes A, Sehn LH, Johnson P, PHOENIX Investigators, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285–1295.
  • Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351–363.
  • Shimada K, Yoshida K, Suzuki Y, et al. Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. Blood. 2021;137(11):1491–1502.
  • Eyre TA, Djebbari F, Kirkwood AA, et al. Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review. Haematologica. 2020;105(7):1914–1924.
  • Savage KJ. Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies. Hematol Am Soc Hematol Educ Program. 2017;2017(1):578–586.
  • Bobillo S, Crespo M, Escudero L, et al. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. 2021;106(2):513–521.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.